VIR

#2049
Vir Biotechnology, Inc. - Common Stock
11.3 1 USD
+0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
11.31
11.31
Jahresspanne
4.81
11.50
Tagesänderung
+2.08%
Monatliche Änderung
+27.94%
6 month change
+27.80%
Jahresänderung
+89.13%
Vorheriger Schlusskurs
11.0 8
Open
11.3 1
Tief
11.3 1
Hoch
11.3 1
Volumen
147
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Vir Biotechnology, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Vir Biotechnology, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Vir Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vir Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Vir Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Vir Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Vir Biotechnology, Inc. current report, Q1 FY2026
8-K

Vir Biotechnology, Inc. current report, Q2 FY2022

Full document

Vir Biotechnology, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated May 20, 2022, details the results of Vir Biotechnology, Inc.'s 2022 Annual Meeting of Stockholders. The record date for the meeting was March 28, 2022, with 132,341,617 shares of common stock outstanding and entitled to vote.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.

Material Changes and Voting Results

Stockholders voted on three proposals at the Annual Meeting:

  • Proposal 1: Election of Directors - Stockholders elected three Class III Directors to serve until the 2025 Annual Meeting.
    • Jeffrey S. Hatfield: 97,249,664 votes For; 4,951,509 votes Withheld.
    • Saira Ramasastry: 94,279,184 votes For; 7,921,989 votes Withheld.
    • George Scangos, Ph.D.: 97,342,218 votes For; 4,858,955 votes Withheld.
  • Proposal 2: Advisory Vote on Executive Compensation - Stockholders approved the compensation of named executive officers.
    • Results: 94,041,769 votes For; 8,061,417 votes Against; 97,987 Abstentions.
  • Proposal 3: Ratification of Independent Auditor - Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
    • Results: 110,979,183 votes For; 113,597 votes Against; 161,702 Abstentions.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Key Facts for Investor Verification

  • Confirmation that the three Class III Directors were successfully elected for a term ending in 2025.
  • Verification of the advisory approval of executive compensation, noting approximately 8 million votes were cast against the proposal.
  • Confirmation that Ernst & Young LLP was ratified as the auditor for the 2022 fiscal year.
  • Review of the total broker non-votes (9,053,309) which impacted the voting totals for Proposals 1 and 2.

Nachrichten